o |
Preliminary
Proxy Statement
|
o |
Confidential,
for use of the Commission only (as permitted by Rule
14a-6(e)(2))
|
o |
Definitive
Proxy Statement
|
||
x |
Definitive
Additional Materials
|
||
o |
Soliciting
Material Under Rule 14a-12
|
|
·
|
the Company’s ability to
obtain necessary regulatory approval for Genasense® from the U.S. Food and Drug
Administration (“FDA”);
|
|
·
|
the safety and efficacy of the
Company’s products or product
candidates;
|
|
·
|
the Company’s assessment of
its clinical trials;
|
|
·
|
the commencement and
completion of clinical
trials;
|
|
·
|
the Company’s ability to
develop, manufacture, license and sell its products or product
candidates;
|
|
·
|
the Company’s ability to enter
into and successfully execute license and collaborative agreements, if
any;
|
|
·
|
the adequacy of the Company’s
capital resources and cash flow projections, the Company’s ability to
obtain sufficient financing to maintain the Company’s planned operations,
or the Company’s risk of
bankruptcy;
|
|
·
|
the adequacy of the Company’s
patents and proprietary
rights;
|
|
·
|
the impact of litigation that
has been brought against the Company;
and
|
|
·
|
the other risks described
under Certain Risks and Uncertainties Related to the Company’s Business,
as contained in the Company’s Annual Report on Form 10-K and Quarterly
Report on Form 10-Q.
|